European biosimilar bevacizumab adoption — the regulatory approval by EMA and subsequent market uptake by national healthcare systems across Germany, France, UK, Italy, Spain, and Scandinavia of multiple biosimilar bevacizumab products beginning in 2017 — creating the most mature and highest-penetration biosimilar bevacizumab market globally and establishing the policy frameworks,...